Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) reported positive preclinical HT-VA CRADA data on April 13, 2026, showing parenteral GDNF reprograms liver fat metabolism at the genetic level.
Key findings include a statistically significant reduction in Srebf1 (lipogenesis), increased Pparα expression (fat burning), and gene-marker outperformance versus semaglutide. Hoth plans further preclinical validation and evaluation of clinical development and partnerships.
Positive
- Statistically significant reduction in Srebf1 (fat-creation gene)
- Increased Pparα expression indicating enhanced fat metabolism
- GDNF outperformed semaglutide on key liver gene-expression markers
- Differentiated, dual mechanism targeting both lipogenesis suppression and fat burning
Negative
- Results are limited to preclinical HT-VA model; clinical efficacy unproven
- No clinical timelines or human safety/efficacy data disclosed
- No quantitative magnitude of gene changes or metabolic endpoints provided
News Market Reaction – HOTH
On the day this news was published, HOTH gained 26.18%, reflecting a significant positive market reaction. Argus tracked a peak move of +69.4% during that session. Argus tracked a trough of -9.3% from its starting point during tracking. Our momentum scanner triggered 44 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $9.86M at that time. Trading volume was exceptionally heavy at 16.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer biotech names show mixed moves, with declines in LSTA (-0.2%) and ELEV (-2.28%) but strong gains in CRIS (+23.98%), PASG (+9.63%) and QTTB (+7.55%). No peers appeared in the momentum scanner, supporting a stock-specific read on the HOTH news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Equity offering closed | Negative | +3.0% | Closing of $2.0M registered direct equity offering and warrants. |
| Apr 01 | Equity offering announced | Negative | -34.9% | Announcement of $2.0M registered direct offering and private warrants. |
| Apr 01 | HT-001 interim results | Positive | -34.9% | Phase 2 interim analysis met primary endpoint with strong symptom relief. |
| Mar 31 | Chinese patent grant | Positive | +9.1% | China granted patent protecting mast cell apoptosis technology to 2039. |
| Mar 26 | AI platform launch | Positive | -6.7% | Deployment of OpenClaw AI platform to accelerate drug discovery pipeline. |
Recent history shows frequent divergences: positive clinical or strategic news has sometimes been followed by sharp declines, while dilutive offerings have seen both drops and rebounds.
Over the past weeks, Hoth combined financing activity with clinical and strategic updates. A $2.0M registered direct offering and concurrent warrants were announced and then closed in early April 2026, with sharply negative and then mildly positive price reactions. A Phase 2 HT-001 interim analysis met its primary endpoint with >65% of patients reporting symptom relief, yet the stock fell about 34.86%. By contrast, a Chinese patent grant on Mar 31 saw a 9.12% gain. The new HT-VA metabolic data adds another program milestone to this mixed reaction pattern.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 14, 2025 allows Hoth to offer up to $50 million of various securities, with at least one usage via a 424B5 prospectus on Apr 2, 2026. This framework enables additional capital raises through prospectus supplements, alongside prior ATM and registered direct activities noted in recent filings.
Market Pulse Summary
The stock surged +26.2% in the session following this news. A strong positive reaction aligns with the clearly favorable genetic and mechanistic data around GDNF in MAFLD and obesity. Historically, Hoth’s newsflow has produced mixed price outcomes, with moves such as +9.12% on a Chinese patent but about -34.86% after positive HT-001 data. Investors would need to balance enthusiasm for differentiated metabolic biology against ongoing losses of $12.5 million in 2025 and a history of equity raises under the $50 million shelf.
Key Terms
crada regulatory
gdnf medical
mafld medical
nash medical
glp-1 agonists medical
srebf1 medical
pparα medical
lipogenesis medical
AI-generated analysis. Not financial advice.
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity
The data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.
- Statistically significant reduction in Srebf1, a key gene driving fat production in the liver
- Increased expression of Pparα, a central regulator of fat metabolism and fat burning
- GDNF outperformed semaglutide in key gene expression markers tied to liver fat regulation
- Demonstrated broad metabolic impact at the genetic level, not just weight reduction
Unlike existing therapies that primarily focus on weight loss, GDNF directly targets the biological mechanisms responsible for fat accumulation in the liver.
- Srebf1 reduction → less fat being created
- Pparα activation → more fat being burned
- Net effect → reprogramming of liver metabolism
This dual mechanism suggests GDNF may offer a disease-modifying approach for MAFLD, obesity, and related metabolic disorders.
"HT-VA represents a major milestone for Hoth as we expand into high-value metabolic indications," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.
"These results demonstrate that GDNF is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists."
SCIENTIFIC SUMMARY (HT-VA STUDY)
The HT-VA study evaluated the effects of parenteral GDNF in a diet-induced obesity and MAFLD model.
Key observations include:
- Western diet significantly increased liver fat accumulation and metabolic dysfunction
- GDNF treatment significantly improved liver gene expression linked to fat metabolism
- Reduced lipogenesis signaling (Srebf1) and enhanced metabolic regulation pathways (Pparα)
- Gene expression changes support improved hepatic lipid handling and metabolic efficiency
STRATEGIC IMPLICATIONS
- Entry into MAFLD/NASH and obesity markets
- Differentiation vs. GLP-1 therapies through gene-level mechanism
- Potential for first-in-class metabolic reprogramming therapy
- Expansion beyond Hoth's core dermatology and oncology pipeline
NEXT STEPS
Hoth plans to:
- Advance HT-VA findings into additional preclinical validation studies
- Evaluate clinical development pathways for metabolic and liver diseases
- Explore strategic partnerships and collaborations to accelerate development
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide-302740965.html
SOURCE Hoth Therapeutics, Inc.